Table 1 Patient characteristics of the patient cohort.

n (% male)

17 (35)

32 (69)

13 (57)

0.045^a

Age [years]

55 ± 2

65 ± 1

69 ± 3

 < 0.001^a,b

BMI [kg/m²]

25.1 ± 1.0

28.4 ± 0.8

27.9 ± 1.1

0.028^a

CRP [mg/l]

3.7 ± 0.6

12.4 ± 5.7

205.3 ± 27.5

 < 0.001^b,c

IL-6 [pg/ml]

4.9 ± 1.2

7.7 ± 1.3

623.8 ± 228.9

 < 0.001^b,c

White blood cell count [× 10³/µl]

6.0 ± 0.4

7.1 ± 0.3

17.2 ± 1.7

 < 0.001^a,b,c

Platelet count [× 10³/µl]

232.0 ± 16.3

255.5 ± 12.6

369.7 ± 45.9

0.032^b

HbA_1c [%]

5.4 ± 0.1

7.0 ± 0.3

5.8 ± 0.3

0.001^a

HbA_1c [mmol/mol]

36.1 ± 1.2

52.7 ± 3.4

39.6 ± 3.0

0.001^a

HOMA-IR [AU]

1.5 ± 0.3

4.1 ± 0.9

4.8 ± 1.6

0.084

Fasting glucose [mmol/l]

7.0 ± 0.4

9.6 ± 0.4

7.1 ± 0.9

 < 0.001^a,c

Creatinine [µmol/l]

67.7 ± 2.6

88.9 ± 4.4

199.6 ± 33.2

 < 0.001^a,b

Albumin [g/l]

38.3 ± 0.7

37.3 ± 0.7

20.2 ± 1.4

 < 0.001^b,c

Bilirubin [µmol/l]

9.9 ± 1.3

9.8 ± 0.8

24.2 ± 5.8

0.011^b,c

ALAT [µmol/l]

0.6 ± 0.1

0.6 ± 0.1

0.9 ± 0.2

0.55

γGT [µmol/l]

0.9 ± 0.2

1.6 ± 0.5

3.0 ± 0.7

0.08

Thromboplastin time [%]

108.1 ± 2.7

99.0 ± 3.9

77.2 ± 2.0

 < 0.001^b,c

Prior laparotomy n [%]

7 (41)

13 (40)

8 (61)

0.41

Malignancy n [%]

11 (65)

26 (81)

8 (61)

0.28

Tumor localization [% total]

Breast

1 (9)

1 (4)

0 (0)

0.54

Colorectal

7 (64)

9 (35)

2 (25)

Hepatobiliary

1 (9)

8 (31)

1 (12)

Kidney

0 (0)

3 (12)

2 (25)

Melanoma

0 (0)

1 (4)

1 (12)

Pancreas

1 (9)

2 (8)

2 (25)

Prostate

0 (0)

1 (4)

0 (0)

Upper GI

1 (9)

1 (4)

0 (0)

Tumor disease stage [% total]

Local

3 (27)

14 (54)

7 (88)

0.03^b

Advanced

8 (73)

12 (46)

1 (12)

Prior chemotherapy n [%]

5 (29)

2 (6)

0 (0)

0.018*

Prior radiotherapy n [%]

4

1

0

0.021*